Pathos dependence on Tempus platform
Pathos
This partnership shows that Pathos is buying speed, but also putting a core part of its moat in another company’s hands. Tempus already sells the raw ingredients Pathos needs, de identified oncology data, trial matching, biological models, and AI tooling. That lets Pathos build faster than a standalone biotech could. But it also means the same supplier can keep moving closer to Pathos’s own position in trial design, target discovery, and drug program economics.
-
The relationship is deep enough to shape Pathos’s roadmap. In April 2025, Pathos, Tempus, and AstraZeneca signed a multi year collaboration to build a multimodal oncology foundation model, with Tempus receiving $200M in data licensing and model development fees. That makes Tempus part of the technical stack, not just a vendor.
-
Tempus is also building the pieces needed to move upstream. Its platform spans real world clinical and molecular data, trial matching through TIME, organoid based biological modeling, and foundation models. Deep 6 added real time EMR based patient finding across 750 plus provider sites and 30 million patients, which strengthens Tempus’s ability to run the enrollment layer itself.
-
The Personalis deal extends Tempus further into longitudinal cancer monitoring through MRD, which means broader reach across the patient journey from diagnosis to treatment selection to recurrence tracking. The more Tempus covers that workflow end to end, the less differentiated a data dependent oncology platform looks unless it also controls proprietary assets and drug upside.
The next phase is likely a split between infrastructure providers and companies that own actual therapeutic programs. Tempus is assembling the full data, model, and trial operating system for oncology. Pathos will need to turn that borrowed infrastructure into compounds, trials, and outcomes that it alone controls, because that is where durable leverage will sit.